USX:CPHD - Cepheid (USD 52.95) Cepheid
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   


Yahoo Finance
Note: This stock seems to be inactive

USD 52.95    +0.0 (+0%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

4 Nov 2016


Overview

4 Nov 2016

Day Change: 0 (0%)

52 Wk Range: 25.09 - 53.91

Day's Range: 52.95 - 53.0

Last Volume: 2,651,121

Current Yield: 0%

Projected Yield: 0%

Open: USD 52.95


Metric CPHD S.Median
Beta NA NA
VaR NA NA
E.Shortfall NA NA
Liquidity NA NA

Fundamental

4 Nov 2016

PE: -103.175

Market Cap: 3.9B

Price Over Book: 10.177

Price Over Sales: 6.5

Return On Assets: -4.4%

Return On Equity: -9.9%

Price Over NAV: [Friends Only]

General

CEO: John L. Bishop

Headquarters: Sunnyvale

Employees: 1,700

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare-associated infections, critical infectious disease, sexual health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow analysis of a sample; and Xpert tests for use on the GeneXpert system. The company sells its products through its direct sales force and distributors worldwide. It has collaboration arrangements with Life Technologies Corporation to develop reagents for use in the USPS BDS program; Foundation for Innovative New Diagnostics to develop tests that can detect mycobacterium tuberculosis and associated rifampin resistance from human sputum samples; and Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation to develop Xpert Ebola, an Ebola test to be run on its GeneXpert Systems. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.